866-997-4948(US-Canada Toll Free)

Global Liver Disease Treatment Market 2017-2021

Published By :

Technavio

Published Date : Jul 2017

Category :

Metabolic Disorders

No. of Pages : 98 Pages

About Liver Disease Treatment
Liver is the largest organ of the body and can completely recover from damage. However, continuous strain on the liver, when treatment is delayed, for a prolonged period of time can lead to severe damage to the liver and can even be fatal.
Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as India and China has led to a higher prevalence of the disease in these countries. There has been a rise in healthcare investment in these countries.
Technavios analysts forecast the global liver disease treatment market to grow at a CAGR of 11.01% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global liver disease treatment market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs in liver disease treatment market.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Liver Disease Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Other prominent vendors
Bristol-Myers Squibb

Johnson and Johnson
Novartis
Salix Pharmaceuticals
Vertex Pharmaceuticals
Market driver
Increase in alcohol-related liver disease
For a full, detailed list, view our report

Market challenge
Side-effects of liver disease treatment drugs
For a full, detailed list, view our report

Market trend
Rise in awareness
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Market landscape
Market overview
Five forces analysis
PART 06: Pipeline landscape
PART 07: Drug class segmentation
Global liver disease treatment market by anti-viral drugs
Global liver disease treatment market by corticosteroids
Global liver disease treatment market by other drugs
Global liver disease treatment market by vaccines
PART 08: Market segmentation by disease type
ARLD
NAFLD
Hepatitis
PBC
Hemochromatosis
PART 09: Geographical segmentation
Liver disease treatment market in Americas
Liver disease treatment market in EMEA
Liver disease treatment market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
Market drivers
Market challenges
PART 12: Market trends
Rise in awareness
Increase in R&D activities for liver cirrhosis medication
Increasing collaborations and M&A
PART 13: Vendor landscape
Competitive scenario
PART 14: Key vendor analysis
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Other prominent vendors
PART 15: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Functions of liver
Exhibit 02: Types of liver diseases
Exhibit 03: Global liver disease treatment market
Exhibit 04: Global liver disease treatment market 2016-2021 ($ billions)
Exhibit 05: Opportunity analysis of global liver disease drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline summary based on vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global liver disease market by drug class
Exhibit 10: Global liver disease treatment market by drug class 2016 and 2021
Exhibit 11: Global liver disease treatment market by anti-viral drugs 2016-2021 ($ billions)
Exhibit 12: HIV treatment regimen approved by FDA
Exhibit 13: Global liver disease treatment market by corticosteroids 2016-2021 ($ billions)
Exhibit 14: Global liver disease treatment market by other drugs 2016-2021 ($ billions)
Exhibit 15: Global liver disease treatment market by vaccines 2016-2021 ($ billions)
Exhibit 16: Vaccination coverage for birth dose of hepatitis B vaccine in various regions 2013
Exhibit 17: Vaccination coverage for three doses of hepatitis B vaccine in various regions 2013
Exhibit 18: Global liver disease treatment market by disease type
Exhibit 19: Stages of ARLD
Exhibit 20: Deaths due to ARLD in US 2014
Exhibit 21: Stages of NAFLD
Exhibit 22: Types of hepatitis
Exhibit 23: Mode of transmission and incubation period of different types of hepatitis
Exhibit 24: Hepatitis A: Key marketed drugs
Exhibit 25: Hepatitis B: Key marketed drugs
Exhibit 26: Hepatitis C: Key marketed drugs
Exhibit 27: Medications for symptoms of PBC
Exhibit 28: Global liver disease treatment market by geography 2016 and 2021
Exhibit 29: Global liver disease treatment market by geography 2016-2021 ($ billions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Liver disease treatment market in Americas 2016-2021 ($ billions)
Exhibit 32: Factors contributing to liver cancer in US
Exhibit 33: Hepatitis infection scenario in US, 2015-2016
Exhibit 34: Market scenario in EMEA
Exhibit 35: Liver disease treatment market in EMEA 2016-2021 ($ billions)
Exhibit 36: Market scenario in APAC
Exhibit 37: Liver disease treatment market in APAC 2016-2021 ($ billions)
Exhibit 38: Top Asian countries in terms of population with diabetes
Exhibit 39: Countries with large populations without adequate sanitation 2014
Exhibit 40: Effects of lifestyle diseases on liver
Exhibit 41: Competitive structure analysis of global liver disease treatment market 2016
Exhibit 42: Strategic success factors of companies in global liver disease treatment market
Exhibit 43: F. Hoffmann-la Roche: Key highlights
Exhibit 44: F. Hoffmann-la Roche: Strength assessment
Exhibit 45: F. Hoffmann-la Roche: Strategy assessment
Exhibit 46: F. Hoffmann-la Roche: Opportunity assessment
Exhibit 47: Gilead: Key highlights
Exhibit 48: Gilead: Strength assessment
Exhibit 49: Gilead: Strategy assessment
Exhibit 50: Gilead: Opportunity assessment
Exhibit 51: GlaxoSmithKline: Key highlights
Exhibit 52: GlaxoSmithKline: Strength assessment
Exhibit 53: GlaxoSmithKline: Strategy assessment
Exhibit 54: GlaxoSmithKline: Opportunity assessment
Exhibit 55: Merck: Key highlights
Exhibit 56: Merck: Strength assessment
Exhibit 57: Merck: Strategy assessment
Exhibit 58: Merck: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *